Regencell Bioscience Net Income Over Time
| RGC Stock | USD 28.45 0.17 0.60% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Regencell Bioscience Performance and Regencell Bioscience Correlation. Regencell | Build AI portfolio with Regencell Stock |
Will Biotechnology sector continue expanding? Could Regencell diversify its offerings? Factors like these will boost the valuation of Regencell Bioscience. Anticipated expansion of Regencell directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Regencell Bioscience data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Regencell Bioscience using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Regencell Bioscience's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Regencell Bioscience's market price to deviate significantly from intrinsic value.
It's important to distinguish between Regencell Bioscience's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Regencell Bioscience should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Regencell Bioscience's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Regencell Bioscience and related stocks such as Cytokinetics, AptarGroup, and Grifols SA ADR Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CYTK | (13.1 M) | (47.9 M) | (41.7 M) | (33.7 M) | (14.6 M) | (37.5 M) | 16.5 M | (127.8 M) | (106.3 M) | (121.7 M) | (127.3 M) | (215.3 M) | (389 M) | (526.2 M) | (589.5 M) | (530.6 M) | (504 M) |
| ATR | 19.5 M | 183.7 M | 162.6 M | 172 M | 191.7 M | 199.3 M | 205.6 M | 220 M | 194.7 M | 242.2 M | 214 M | 244.1 M | 239.3 M | 284.5 M | 374.5 M | 430.7 M | 452.3 M |
| GRFS | 25.6 M | 50.3 M | 256.7 M | 345.6 M | 470.3 M | 532.1 M | 545.5 M | 662.7 M | 596.6 M | 625.1 M | 618.5 M | 188.7 M | 185 M | 42.3 M | 156.9 M | 180.5 M | 320.1 M |
| ABVX | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.1 M) | (16 M) | (14.3 M) | (11.2 M) | (15.8 M) | (30.6 M) | (37.6 M) | (42.5 M) | (60.7 M) | (147.7 M) | (176.2 M) | (158.6 M) | (150.7 M) |
| RYTM | (18.1 M) | (18.1 M) | (18.1 M) | (21.4 M) | (6.5 M) | (11.1 M) | (25.9 M) | (33.7 M) | (74.1 M) | (134.6 M) | (130.7 M) | (68 M) | (181.1 M) | (184.7 M) | (260.6 M) | (234.5 M) | (222.8 M) |
| STVN | 39.2 M | 39.2 M | 39.2 M | 39.2 M | 39.2 M | 39.2 M | 39.2 M | 39.2 M | 39.2 M | 39.2 M | 78.5 M | 134.3 M | 142.8 M | 145.6 M | 117.8 M | 135.4 M | 120.7 M |
| AXSM | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (6 M) | (12.2 M) | (27.2 M) | (28.9 M) | (31 M) | (68.3 M) | (102.9 M) | (134.9 M) | (187.1 M) | (239.2 M) | (287.2 M) | (258.5 M) | (245.6 M) |
| NUVL | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (14.6 M) | (46.3 M) | (73.3 M) | (126.2 M) | (260.8 M) | (234.7 M) | (222.9 M) |
| MASI | (6.5 M) | 63.7 M | 62.3 M | 58.4 M | 72.5 M | 83.3 M | 300.7 M | 131.6 M | 193.5 M | 196.2 M | 240.3 M | 229.6 M | 143.5 M | 81.5 M | (304.9 M) | (350.6 M) | (333.1 M) |
Regencell Bioscience and related stocks such as Cytokinetics, AptarGroup, and Grifols SA ADR Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Regencell Bioscience financial statement analysis. It represents the amount of money remaining after all of Regencell Bioscience Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Regencell Bioscience Holdings | RGC |
| Classification | Compulsion |
| Business Address | Chinachem Leighton Plaza, |
| Exchange | NASDAQ Exchange |
USD 28.45
Check out Regencell Bioscience Performance and Regencell Bioscience Correlation. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Regencell Bioscience technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.